- Home
- BFRI vs KZIA Comparison
BFRI vs KZIA Comparison
Compare BFRI & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFRI
- KZIA
- Stock Information
- Founded
- BFRI 1997
- KZIA 1994
- Country
- BFRI United States
- KZIA Australia
- Employees
- BFRI N/A
- KZIA N/A
- Industry
- BFRI Biotechnology: Pharmaceutical Preparations
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- BFRI Health Care
- KZIA Health Care
- Exchange
- BFRI Nasdaq
- KZIA Nasdaq
- Market Cap
- BFRI 6.2M
- KZIA 6.0M
- IPO Year
- BFRI 2021
- KZIA 1999
- Fundamental
- Price
- BFRI $1.11
- KZIA $0.88
- Analyst Decision
- BFRI Strong Buy
- KZIA Strong Buy
- Analyst Count
- BFRI 1
- KZIA 2
- Target Price
- BFRI $7.00
- KZIA $11.50
- AVG Volume (30 Days)
- BFRI 158.3K
- KZIA 5.5M
- Earning Date
- BFRI 03-14-2025
- KZIA 03-26-2025
- Dividend Yield
- BFRI N/A
- KZIA N/A
- EPS Growth
- BFRI N/A
- KZIA N/A
- EPS
- BFRI N/A
- KZIA N/A
- Revenue
- BFRI $35,358,000.00
- KZIA $1,655,324.00
- Revenue This Year
- BFRI $17.69
- KZIA N/A
- Revenue Next Year
- BFRI $19.71
- KZIA N/A
- P/E Ratio
- BFRI N/A
- KZIA N/A
- Revenue Growth
- BFRI 5.17
- KZIA 248000.00
- 52 Week Low
- BFRI $0.65
- KZIA $0.85
- 52 Week High
- BFRI $2.43
- KZIA $15.80
- Technical
- Relative Strength Index (RSI)
- BFRI 49.87
- KZIA 29.00
- Support Level
- BFRI $1.06
- KZIA $0.90
- Resistance Level
- BFRI $1.16
- KZIA $1.60
- Average True Range (ATR)
- BFRI 0.07
- KZIA 0.14
- MACD
- BFRI -0.00
- KZIA 0.02
- Stochastic Oscillator
- BFRI 55.00
- KZIA 4.00
About BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.